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West Lafayette, IndianaABSTRACT A mechanistic understanding of the intermolecular interactions and structural changes during fibrillation is crucial
for the design of safe and efficacious glucagon formulations. Amide hydrogen/deuterium exchange with mass spectrometric
analysis was used to identify the interactions and amino acids involved in the initial stages of glucagon fibril formation at acidic
pH. Kinetic measurements from intrinsic and thioflavin T fluorescence showed sigmoidal behavior. Secondary structural mea-
surement of fibrillating glucagon using far-UV circular dichroism spectroscopy showed changes in structure from random coil/
a-helix / b-sheet, with increase in a-helix content during the lag phase followed by increase in b-sheet content during the
growth phase. Hydrogen/deuterium exchange with mass spectrometric analysis of fibrillating glucagon suggested that C-termi-
nal residues 22–29 are involved in interactions during the lag phase, during which N-terminal residues 1–6 showed no changes.
Molecular dynamics simulations of glucagon fragments showed C-terminal to C-terminal interactions with greater a-helix content
for the 20–29 fragment, with hydrophobic and aromatic residues (Phe-22, Trp-25, Val-23, and Met-27) predominantly involved.
Overall, the study shows that glucagon interactions during the early phase of fibrillation are mediated through C-terminal resi-
dues, which facilitate the formation of a-helix-rich oligomers, which further undergo structural rearrangement and elongation to
form b-sheet-rich mature fibrils.INTRODUCTIONSome soluble peptides and proteins can self-assemble to
form ordered, insoluble, b-sheet-rich fibers called amyloid
fibrils. More than 20 different human proteins are known
to form amyloid fibrils and several are responsible for
diseases such as Alzheimer’s disease and prion disorders
(e.g., Creutzfeldt-Jakob disease) (1,2). Recent studies sug-
gest that the toxicity of these proteins is due to the accumu-
lation of prefibrillar intermediates, rather than the mature
fibrils themselves (3–5). However, detailed structural char-
acterization of these transient intermediates is often difficult
and they typically are not amenable to conventional high-
resolution methods such as x-ray crystallography. As a
result, fibrillation has often been characterized by a combi-
nation of analytical methods, including thioflavin T (ThT)
staining, circular dichroism (CD) spectroscopy, Fourier
transform infrared spectroscopy, fiber diffraction patterns,
atomic force microscopy (AFM), transmission electron
microscopy, small-angle x-ray scattering, and NMR spec-
troscopy (6–8). These methods are limited in that they are
only semiquantitative, lack structural resolution, and/or
require relatively large amounts of the peptide or protein.
In the studies reported here, amide hydrogen/deuterium
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0006-3495/15/02/0937/12 $2.00has been used to identify the early stage interactions and
structural changes in the fibrillation of human glucagon
with peptide-level resolution.
Glucagon is a 29-amino acid peptide hormone that in-
creases blood glucose levels and is used in the treatment
of severe hypoglycemia. Though administered by injecting
a solution, glucagon is unstable in the solution form (9,10)
and the commercial product is marketed as a lyophilized
solid. The formation of fibrillar aggregates is arguably the
most serious type of degradation in glucagon, because it oc-
curs rapidly under a wide range of conditions and increases
solution viscosity, making injection difficult. For peptide
and protein drugs in general, the presence of aggregates
is associated with the potential for changes in potency and
an increased risk for life-threatening immunogenic side
effects, an even greater concern. To ensure that glucagon
is administered to patients in a safe and fully potent form,
the lyophilized drug product is reconstituted in dilute acidic
buffer just before administration, and any surplus solution is
discarded immediately.
Inhibiting glucagon fibrillation is critical to the develop-
ment of a stable solution formulation and to ensuring the
safety and efficacy of reconstituted solids. Various strategies
have been attempted to achieve this goal. The design of
aggregation-resistant glucagon analogs has been shown to
be beneficial in some cases (11,12). Methionine (Met-27)
oxidation has been shown to greatly delay the fibrillation
of unmodified glucagon (10), suggesting that mutationshttp://dx.doi.org/10.1016/j.bpj.2015.01.004
938 Moorthy et al.near the C-terminus may be particularly effective.
PEGylation has enhanced the physical stability of glucagon
under various conditions (13). However, any changes to the
amino acid sequence or structure of a small peptide such
as glucagon may impact biological activity (14–19), and
so are not without risk. Attempts to stabilize glucagon using
readily available formulation additives have generally been
ineffective or limited in their ability to stabilize the native
structure (20–22).
The rational design of fibrillation-resistant glucagon re-
quires a thorough understanding of the mechanisms of its
self-assembly, with particular attention to the early phases
of fibrillation and the regions that participate in early stage
interactions. Though there have been numerous studies of
glucagon fibrillation (23–29), the molecular mechanisms
involved have not been well studied, due in part to the rapid
fibrillation kinetics and the lack of high-resolution methods.
As with other amyloidogenic peptides and proteins,
glucagon fibrillation is a complex process. which includes
molecular interactions, the formation of intermediate states,
structural transitions, and the assembly of oligomers to form
fibrils (23,24). Complexity is further increased by structural
polymorphism in the fibrils themselves, which results from
changes in concentration, solvent composition, and temper-
ature (24,30). Several studies have shown that both hydro-
phobic and charged amino acids in the glucagon sequence
are critical for fibrillation (28,29,31–34). Some suggest
that the hydrophobic residues in the N- and C-terminus
are involved (32), whereas others argue that only the
N-terminal region participates (28). The results from these
studies have been based either on analysis of mutants or
characterization of the mature fibrils, rather than on studies
of native glucagon itself, and may depend on solution
composition and temperature.
In this study, we used HDX-MS and other biophysical
measurements to monitor the sequence of structural events
in glucagon during fibrillation under acidic conditions,
from loss of monomer to the development of mature fibrils.
Pulsed HDX with MS analysis has been used successfully
to capture the molecular interactions and transient interme-
diates during fibrillation of other proteins (35–38). HDX-
MS has also been used to characterize glucagon fibrillation
at neutral pH (34), though local structural changes during
the early stages of fibril formation were not investigated.
We conducted HDX at pH 4.5, where the rate of exchange
is ~1000-fold slower than at pH 7.4, the pH used in the pre-
vious study (34). The lower pH allows the molecular inter-
actions and conformational changes during the early stages
of glucagon fibrillation to be monitored at a range of HDX
reaction times. The results from HDX-MS, far-UV CD spec-
troscopy, and molecular dynamics (MD) simulations show
that the unstructured monomers self-associate through the
C-terminus to form a-helix-rich oligomers during the lag
phase of glucagon fibrillation. The oligomers then undergo
structural changes with an increase in b-sheet content duringBiophysical Journal 108(4) 937–948the transition to the mature fibrils. Overall, the work iden-
tifies the C-terminus as the region responsible for the early
stages of glucagon fibrillation at acidic pH. Thus, inhibiting
C-terminal self-association is expected to be an effective
approach to stabilizing solution formulations of glucagon
under these conditions.MATERIALS AND METHODS
Materials
Research grade human glucagon was purchased from ProSpec (East Bruns-
wick, NJ). 96-well black and crystal-clear microplates were purchased from
Greiner Bio-One (Frickenhausen, Germany). ThT was purchased from
Abcam (Cambridge, MA). MS spectrometry grade water, acetonitrile
(ACN) and formic acid (FA) were from ThermoFisher Scientific (Waltham,
MA). Deuterium oxide (D2O) (99.9%) was purchased from Cambridge
Isotope Laboratories (Andover, MA). Poroszyme Immobilized Pepsin,
Bulk Media was purchased from Applied Biosystems (Foster City, CA)
and packed into a high-performance liquid chromatography column
(50 2.1 mm, Grace Davison Discovery Sciences, Deerfield, IL). All other
chemicals used were at least reagent grade and used as received.Intrinsic fluorescence measurement
The fluorescence emission fromTrp-25 in glucagonwasmeasured over time
during fibrillation. A 0.6 mg/mL glucagon solution was prepared in 3.2 mM
HCl, 0.9% NaCl (w/v) (pH 2.5), and centrifuged at 14,000 rpm for 3 min to
remove any insolublematerial. Samples in triplicatewere quickly transferred
to a 96-well black microtiter plate and placed in a BioTek Synergy 4 Multi-
Detection microplate reader (BioTek Instruments, Winooski, VT). The
excitation and emissionwavelengthswere set to 295 nm and 355 nm, respec-
tively, and measurement was carried out for 8 h at 23C at 15-min intervals
preceded by 5 s automixing before each reading. The data were fitted to the
Boltzmann equation (a sigmoidal function) as given by
Y ¼ A2 þ A1  A2
1þ eðxx0Þ=dx; (1)
where A1 is the minimum signal, A2 is the maximum signal, x0 is the time at
which the change in signal is 50% (t50), dx is the time constant, and the lag
time is estimated by x0 – 2 dx.ThT fluorescence measurement
Glucagon at 0.6 mg/mL in 3.2 mM HCl, 0.9% NaCl (w/v) (pH 2.5) was
incubated with 50 mM ThT. Samples in triplicate were quickly transferred
to a 96-well black flat bottommicrotiter plate and placed in the BioTek Syn-
ergy 4 Multi-Detection microplate reader (BioTek Instruments, Winooski,
VT). Fibrillation was followed by measuring the fluorescence intensity of
ThT with the excitation and emission wavelengths set to 440 nm and
482 nm, respectively. Measurements were carried out at 15-min intervals
for 8 h at 23C with 5 s automixing before each reading. The data were
fitted to the Boltzmann equation (Eq. 1) as described previously.Turbidity measurement
Samples containing 0.6 mg/mL of glucagon in 3.2 mM HCl, 0.9% NaCl
(w/v) (pH 2.5) were prepared in triplicate and incubated in 96-well crys-
tal-clear microtiter plates. The turbidity of the solutions was measured by
UV absorbance at 405 nm at 15-min intervals using a BioTek Synergy 4
Multi-Detection microplate reader (BioTek Instruments). Measurements
Glucagon Fibrillation 939were carried out for 8 h at 23C with 5 s automixing before each reading.
The data were fitted to the Boltzmann equation (Eq. 1).CD spectroscopy
To monitor structural changes in glucagon during fibrillation, glucagon
at 0.6 mg/mL in 3.2 mM HCl, 0.9% NaCl (pH 2.5) was allowed to fibrillate
for 24 h. Samples were withdrawn at regular intervals, diluted to 0.3 mg/mL
in 3.2 mM HCl, 0.9% NaCl (pH 2.5), and subjected to CD spectroscopy
using a JASCO J-815 spectrometer (JASCOAnalytical Instruments, Easton,
MD). Spectra were collected in the far-UV range between 190 and 250 nm
using a 1 mm path length cell with 0.2 nm bandwidth at 20C. Each spec-
trum was an average of three scans with a scanning speed of 50 nm/min. CD
spectra were analyzed using the online K2D3 program to estimate the sec-
ondary structure at each time point (39).Amide HDX-MS
To determine the extent of deuterium uptake by glucagon, samples were
prepared containing 0.6 mg/mL of glucagon in 3.2 mM HCl, 0.9% NaCl
(w/v), pH 2.5, and centrifuged at 14,000 rpm for 3 min to remove any insol-
uble material. In-exchange was initiated by diluting the freshly prepared
sample 10-fold in deuterated buffer containing 10 mM sodium citrate and
0.9% NaCl (w/v) (pHread 4.5), resulting in a final concentration of 90%
D2O and 17 mM glucagon. Exchange was allowed to proceed at 23
C
and samples withdrawn at various times (0.5–120 min). Each 20 mL sample
was quenched by rapidly mixing with 40 mL of ice-cold solution containing
5 M urea, 5% methanol, and 0.2% FA (pH 2.5) and then flash frozen in
liquid nitrogen and stored at 80C until analysis.
To monitor glucagon fibrillation kinetics using HDX-MS, glucagon sam-
ples (0.6 mg/mL in 3.2 mM HCl, 0.9% NaCl, pH 2.5) were prepared and
allowed to fibrillate at 23C for 24 h. At various times during fibrillation,
5 min pulse labeling with deuterium was carried out. Pulse labeling was
initiated by diluting a 2 mL sample of fibrillating glucagon in 18 mL of
deuterated buffer containing 10 mM sodium citrate and 0.9% NaCl (w/v)
(pHread 4.5), resulting in a final concentration of 90% D2O and 17 mM
glucagon. The pulse-labeled samples were quenched and stored at 80C
as described previously until analysis.
To determine the extent of deuterium uptake by the mature fibrils,
glucagon at 0.6 mg/mL was allowed to fibrillate at 23C for 48 h. Triplicate
50 mL samples were centrifuged at 4000 rpm for 5 min to separate the fibril
from supernatant. After discarding the supernatant, the fibrils were washed
thrice with 500 mL of blank buffer (3.2 mM HCl, 0.9% NaCl (w/v), pH
2.5) to remove any nonfibrillar glucagon present in the samples. HDX was
initiated by incubating fibrils in 50 mL of deuterated buffer (99% D2O) con-
taining 10 mM sodium citrate and 0.9% NaCl (w/v) (pHread 4.5) at 23
C for
48 h.Reactionswere quenched by quickly adding100mLof ice-cold solution
containing 5 M urea, 5% methanol, and 0.2% FA (pH 2.5). Samples were
flash frozen in liquid nitrogen and stored at 80C as described previously.
Deuterium uptake was assessed for both intact glucagon and for proteo-
lytic digests. For intact glucagon, deuterium uptake was measured using a
high-performance liquid chromatography mass spectrometry (LC/MS) sys-
tem (1200 series LC, 6520 Q-TOF; Agilent Technologies, Santa Clara, CA)
equipped with a custom-built refrigeration unit that maintained the column
at ~0C. The samples were quickly thawed and ~28 pmole of glucagon was
injected into a peptide microtrap (Michrom Bioresources, Auburn, CA).
Samples were desalted for 2 min with 15% ACN, 85% water, and 0.1%
FA and eluted in 2.3 min using a gradient to 90% ACN, 10% water, and
0.1% FA. Mass spectra were obtained over the m/z range 100–1700. For
samples subjected to proteolytic digestion, ~55 pmole of glucagon was in-
jected into an immobilized pepsin column. Online digestion was carried out
in water containing 0.1% FA at a flow rate of 0.2 mL/min. The digested
sample was desalted in a peptide microtrap for 1.7 min and eluted using
a gradient of ACN (10–60%) in 0.1% FA onto a reverse phase analyticalcolumn (Zorbax 300SB-C18; Agilent Technologies, Santa Clara, CA) at
50 mL/min. Undeuterated glucagon samples were also analyzed and their
mass measured by tandem mass spectrometry (MS/MS) analysis (colli-
sion-induced dissociation fragmentation; MassHunter Software; Agilent
Technologies). Peptides identified using undeuterated glucagon were map-
ped onto subsequent deuteration experiments using the semiautomated
HX-Express software to obtain the average number of deuterons exchanged
(40). For peptides showing a bimodal distribution of deuterium uptake, the
percent deuteration was calculated from the weighted average of deuterium
uptake in the accessible and protected populations. The bimodal spectral en-
velopes were fitted to the sum of two Gaussian distributions using OriginPro
8.6, and the relative area under each peak used to obtain the percentage of
each population at different times during fibrillation. As the time between
thawing and mass spectrometric analyses for all the HDX samples were
very similar, thevalues obtainedwere not subjected to back exchange correc-
tion. All values are themean of at least three independent HDX experiments.
The HDX kinetics of freshly prepared glucagon were fitted to a monoex-




where Dmax is the maximum deuteration at equilibrium, k is the rate con-
stant, and t is deuteration time (min).
Deuterium uptake data from the peptides of fibrillating glucagon were
fitted to a monoexponential decay model (Eq. 3):
D ¼ ðD0  DNÞekt þ DN; (3)
where D0 is the deuterium uptake at t ¼ 0 of fibrillation, DN is the deute-
rium uptake at t¼N of fibrillation; and k and t are the rate constant and the
fibrillation time, respectively.MD simulation
Initial structures of the N-terminal (residues 1–8) and C-terminal (residues
22–29) fragmentswere generated from reportedNMRstructures of glucagon
(Protein Data Bank (PDB) ID: 1KX6) (41). Three different models were
selected as starting configurations for MD simulations, and are referred to
as models 1, 5, and 10 in keeping with the numbering in the ensemble of
NMR models in the original PDB file. In simulations of the interactions of
two molecules of either the 1–8 fragment or the 22–29 fragment, the mole-
cules were initially placed close to one another with arbitrary relative initial
orientation, maintaining at least a 4 A˚ distance between any two atoms in the
two fragments. Combining the conformations of the three NMR models for
each fragment, three starting configurations were generated for each of the
N-terminal and C-terminal fragment simulations. Specifically, starting con-
figurations for both the N-terminal fragment (1–8) and the C-terminal frag-
ment (22–29) simulations were: model 1 with model 5, model 1 with model
10, and model 5 with model 10. All simulations were performed on capped
peptides (i.e., N-terminus acetylated and C-terminus amidated) and the side
chains ofHis residues in theN-terminal fragmentswere doubly protonated to
represent the most likely state in solution at pH 2.5.
To simulate the interactions of peptide fragments, the molecules were
solvated in a preequilibrated octahedron of TIP3P water molecules, with
a minimum distance of 10 A˚ between the octahedron boundary and solute
atoms (42). Production simulations were performed in an NPTensemble us-
ing the AMBER-99SB force field with periodic boundary conditions and an
integration time step of 2 fs, applying the particle mesh Ewald method to
treat electrostatic interactions (43). All bonds involving hydrogen atoms
were constrained using the SHAKE algorithm (44) and van der Waals inter-
actions were truncated at a distance of 10 A˚. A Langevin thermostat (45)
with collision frequency of 1 ps1 was used to maintain the temperature
at 298 K, and pressure was maintained at 1 atm using isotropic position
scaling with a pressure relaxation time of 2 ps. The N-terminal 1–8Biophysical Journal 108(4) 937–948
TABLE 1 Kinetic parameters for glucagon fibrillation as
determined by intrinsic (Trp) fluorescence, ThT fluorescence,
and turbidity measurements
Measurement Lag timea (min) t50
a (min)
Trp fluorescence 1645 2 2125 1
ThT fluorescence 2045 2 2635 2
Turbidity 1485 3 2305 1
an ¼ 3, mean 5 SD.
940 Moorthy et al.fragment simulation was neutralized by the addition of one Cl ion per
fragment. In a simulation, the water molecules with constrained peptide(s)
first were energy minimized. The system was then gradually heated from
0 K to 298 K over a 20 ps MD simulation period. The system was then
equilibrated at constant temperature and pressure for 200 ps and final pro-
duction runs performed for 100 ns. Snapshots were saved every 0.05 ns,
resulting in 2000 snapshots for each production simulation.
A contact between residues from two molecules was identified if a dis-
tance <5 A˚was observed between any pair of atoms. Only contacts formed
between two different peptide molecules were analyzed, and not those
within a single strand. All MD snapshots of the simulations were considered
for contact analysis. The frequencies of observing contacts were first
analyzed for the three separate simulations of two molecules, and then aver-
aged over all three simulations to obtain a single mean contact frequency.
The a-helix content of each snapshot was analyzed using the DSSP
software (46,47). In simulations of two interacting peptides, snapshots
were analyzed separately for each peptide. For each amino acid, the per-
centage of snapshots in which it was part of an a-helix substructure was
computed for all simulations, and the mean structural content of the various
single and two peptide molecule(s) simulations was computed. Molecules
were visualized in PyMOL (48–50) and the graphs were generated using
Python and matplotlib (51).RESULTS
Fibrillation kinetics using fluorescence and
turbidity measurements
During fibrillation, a decrease in intrinsic fluorescence and an
increase in ThT fluorescencewith timewere observed (Fig. 1
and Table 1). The decrease in intrinsic fluorescence is consis-
tent with a change in the environment of the single fluores-
cent amino acid (Trp-25), which is solvent exposed in
monomeric glucagon (24) and may become buried in the
relatively hydrophobic environment produced by the fibrils.
The increase in ThT fluorescence is consistent with the for-
mation of b-sheet structures in the developing fibrils. An
increase in turbidity was observed (Fig. 1 and Table 1) and
is consistent with increasing particle number and/or size ofFIGURE 1 Kinetics of glucagonfibrillationby intrinsic fluorescence (solid
circle), ThT fluorescence (solid square), and turbidity (solid diamond) mea-
surements. Glucagon at 0.6 mg/mL was allowed to fibrillate and the change
in signals were measured. Lines are fits to the Boltzmann equation (n ¼ 3,
mean5 SD). The regression parameters are given in Table 1.
Biophysical Journal 108(4) 937–948particles as fibrillation proceeds. Fibrillation kinetics were
characterized by lag, growth, and equilibrium phases, as re-
ported previously for glucagon (24). Both fluorescence and
turbidity signals follow a sigmoidal curve, which is charac-
teristic of nucleation-dependent fibrillation (21,24). The lag
times for fibrillation as measured by turbidity, intrinsic fluo-
rescence, and ThT fluorescence were 1485 3 min, 1645
2min, and 20452min, respectively. Similarly, the t50 values
for turbidity, intrinsic fluorescence, and ThT fluorescence
measurements were found to be 230 5 1 min, 212 5
1 min, and 263 5 2 min, respectively (Table 1). Because
the lag time and t50 value were greater when measured by
the ThTassay than when measured by intrinsic fluorescence,
suggests that the formation of b-sheet-rich amyloid fibrils is
preceded by the formation of oligomeric intermediates. The
shortest lag time and t50 values were observed with turbidity
measurements, implying that particles are detected before
the detection of changes in structure by the other two
methods. Due to differences in the methods and their limits
of detection, however, these quantitative comparisons should
be regarded as approximate.Secondary structure changes during fibrillation
by CD spectroscopy
CD spectroscopy has been used to study structural changes
during amyloid fibrillation of proteins and peptides (52–57).
Here, a total of 17 far-UV CD spectra acquired at different
times were overlaid to show secondary structural changes
during fibrillation (Fig. 2 A). Changes in the CD spectra
are consistent with changes in secondary structure from
random coil/ a-helix/ b-sheet during fibrillation. The
solution structure of freshly prepared (t ¼ 0 min) glucagon
was primarily random coil with a negative band around
195 nm. An increase in a-helix content was observed for
fibrillating glucagon, with the emergence of negative bands
around 220 and 208 nm. The predicted structural composi-
tion shows maximal a-helix content at 150 min (Fig. 2). CD
spectra at later times (180–1440 min) are consistent with
increased b-sheet content, with negative and positive bands
at 218 nm and 195 nm, respectively (Fig. 2).Amide HDX-MS for monomeric glucagon
HDX of freshly prepared glucagon was carried out by
diluting the samples 10-fold with D2O to give a final
FIGURE 2 Structural changes during glucagon fibrillation. CD measure-
ments were carried out at regular intervals for the fibrillating glucagon. (A)
Overlay of CD spectra from fibrillating glucagon (0–1440 min). (B) Percent
a-helix (solid line) and b-sheet (dashed line) content determined using the
K2D3 program. To see this figure in color, go online.
FIGURE 3 HDX kinetics for monomeric glucagon. HDX reactions were
carried out for freshly prepared glucagon. Samples were withdrawn at
various times (0.5–120 min) and analyzed using MS. Deuterium uptake
was assessed for both intact glucagon and for proteolytic digests. (A) Deute-
rium uptake for intact glucagon as a function of time (0.5–120 min). Lines
are fits to a monoexponential association function (Eq. 2) (n ¼ 3). Standard
deviations are less than the size of the symbols. The vertical dotted line in-
dicates the half-life (t1/2 ¼ 5.3 min). (B) Percent deuterium uptake for nine
pepsin digest fragments from glucagon as a function of time (0.5–30 min)
(n ¼ 3).
Glucagon Fibrillation 941glucagon concentration of 60 mg/mL. Dilution is assumed to
effectively quench fibrillation, although having little to no
effect on the extent of deuterium uptake by monomeric
glucagon. An increase in deuterium uptake was observed
over the HDX time course, together with a single
Gaussian-shaped isotope distribution, with no new peaks
or significant peak broadening at any time point (Fig. S1
in the Supporting Material). The relationship between the
number of deuterons incorporated and time was fitted to a
monoexponential association model, with a resulting half-
life (t1/2) of 5.3 min (Fig. 3 A). The half-life suggests that
5-min pulse labeling is adequate to monitor the structural
changes during glucagon fibrillation, providing sufficient
deuterium uptake (Fig. 3 A) without requiring too large a
fraction of the fibrillation time course (Fig. 1).
Deuterium uptake in monomeric glucagon was also moni-
tored at the peptide level following pepsin digestion. A total
of 18 peptic fragments were detected by LC/MS. Of these,
nine were selected (1–6, 1–9, 7–21, 10–21, 17–22, 22–26,22–29, 23–29, 26–29) having reproducible strongMS signals
and providing 100% sequence coverage with some overlap
(Fig. S2). After 30 min of deuterium exposure, peptides 1–
6, 1–9, and 26–29 showed 80% deuterium uptake, whereas
fragments 7–21, 10–21, 17–22, and 22–26 showed ~65%
deuterium uptake (Fig. 3 B). Although this suggests some
protection in the central portion of the glucagon molecule,
the overall pattern and kinetics of exchange suggest that
the molecule is unstructured, with uniform increase in deute-
rium incorporation along the sequence.Amide HDX-MS for fibrillating glucagon
During fibrillation, the initial (t ¼ 0) deuterated mass enve-
lope is unimodal. After 15 min of fibrillation, a new peakBiophysical Journal 108(4) 937–948
942 Moorthy et al.envelope was observed (Peak I) with lower m/z and greater
protection from exchange (Fig. 4 A). Generally, reduced
deuterium uptake in HDX is consistent with greater confor-
mational stability and/or greater protection from solvent
(36). Here, we infer that Peak I corresponds to a-helical
glucagon, or to glucagon oligomers, or early fibrils, which
are protected from deuterium incorporation by intermolec-
ular association and dissociate into monomers before LC/
MS analysis. The intensity of Peak I increases with time,
and the overall deuterium uptake (i.e., the weighted average
of deuterium incorporation into the two peaks) decreases
over time, providing additional support for this inferenceFIGURE 4 HDX-MS of fibrillating glucagon at the intact level. A 5 min pul
regular intervals (0–480 min) and deuterium uptake measured by MS analy
871.1729, z ¼ þ4) showing bimodal peak distribution (Peak I and II) during fi
envelope after 0 min and 1440 min of fibrillation, respectively. (B) Glucagon fi
circle), ThT florescence at 482 nm (solid square), turbidity at 405 nm (solid di
mean 5 SD). See text for details of methods and calculations.
Biophysical Journal 108(4) 937–948(Fig. 4 B). By 480 min of fibrillation, Peak II was no longer
detected, indicating a complete shift in the population
from monomeric to oligomeric glucagon. The amount of
deuterium uptake as a function of fibrillation time (15–
480 min) was fitted to a monoexponential decay model.
A significantly shorter half-life (t50 ¼ 114 5 2 min) was
observed for HDX than for Trp fluorescence (t50 ¼ 212 5
1 min), turbidity (t50 ¼ 2305 1 min), or ThT fluorescence
(t50¼ 2635 2 min) measurements. This suggests that HDX
probes structural changes and interactions that precede the
changes measured by the other methods. A small decrease
in the level of deuterium uptake was also observed forse labeling with deuterium was carried out for the fibrillating glucagon at
sis. (A) Enhanced deuterated mass envelope of intact glucagon (m/z ¼
brillation. Gray and black broken lines represent the centroid of the mass
brillation as monitored by tryptophan (Trp-25) emission at 355 nm (solid
amond), and deuterium uptake by amide HDX-MS (solid triangle) (n ¼ 3,
Glucagon Fibrillation 943Peak I and Peak II with increase in fibrillation time
(Fig. S3), suggesting the existence of intermediates within
each population.Amide HDX-MS for fibrillating glucagon at the
peptide level
To identify the particular regions of the glucagon sequence
that are protected from HDX in the early stages of fibril
formation, samples were subjected to proteolytic digestion
before MS analysis. A total of nine overlapping peptides
covering 100% of the glucagon sequence were identified
and analyzed (Fig. S2). A decrease in deuteration with
time was observed for all peptides (Figs. S4, 5 A, and
S5), with the rate of decrease varying among the frag-
ments. During fibrillation, overlapping fragments, 1–6
and 1–9 from the N-terminal region showed a decrease
in deuterium uptake at a much slower rate than fragments
from other regions, with t50 values ~5 and ~3 greater,
respectively, than for the other peptides (Fig. 5 B). PepticFIGURE 5 Interactions during glucagon fibrillation monitored by amide
HDX-MS. A 5 min pulse labeling with deuterium was carried out for fibril-
lating glucagon at regular intervals (0–480 min). The deuterium uptake was
measured by MS analysis following online pepsin digestion (A) Percent
deuterium uptake for peptides 1–6, 1–9, 10–21, and 22–29 as a function
of time of fibrillation. Lines represent fits to monoexponential decay; see
text for details (n¼ 3, mean5 SD). (B) t50 values for the decrease in deute-
rium incorporation in the nine glucagon fragments (n ¼ 35 SE).fragments 1–6, 1–9, and 10–21 still showed ~25%, ~14%,
and ~10% deuterium uptake, respectively, after 1440 min,
whereas deuterium incorporation for the C-terminus (resi-
dues 22–29) was <1% after only 480 min of fibrillation
(Figs. 5 A and S4). For the C-terminus, both the relatively
rapid decrease in deuterium incorporation and the near-
zero incorporation after 480 min suggest that this region
is involved in the early stages of glucagon fibrillation.
This result is consistent with the prediction of aggregation
prone regions using AGGRESCAN and TANGO software
(Fig. S6). Conversely, peptide 1–6 showed ~60% deute-
rium uptake from t ¼ 0 to 120 min with decreased deuter-
ation only after 180 min, suggesting that this region does
not participate in early fibrillation (Figs. 5 A and S4).
Peptides 1–9, 10–21, and 22–29 showed intermediate
behavior.Amide HDX-MS of mature glucagon fibrils
To identify the solvent accessible regions in mature fibrils,
glucagon was allowed to fibrillate at pH 2.5 for 48 h and
then exposed to D2O for up to an additional 48 h. The
deuterated fibrils showed a bimodal mass envelope on
MS analysis, with a second peak (Peak II0) showing
increased deuterium incorporation appearing after 48 h
of HDX (Fig. S7). Deuterium uptake values for the Peak
I0 populations of peptic fragments 1–9, 10–21, and 22–
29 after 48 h were ~2%, ~6%, and ~1%, respectively
(Fig. 6), indicating high protection from exchange consis-
tent with interactions within the fibril. In contrast, peptic
fragments 1–9, 10–21, and 22–29 in Peak II0 populations
showed ~64%, ~80%, and ~77% deuterium uptake,
respectively, with region 10–29 more exposed than the
N-terminal fragment (Fig. 6). The relative intensities of
Peak II0 relative to Peak I0 (i.e., [Peak II0 intensity/
Peak I0 intensity]  100) for fragments 1–9, 10–21, andFIGURE 6 HDX-MS of mature glucagon fibrils. Glucagon at 0.6 mg/mL
was allowed to fibrillate and subjected to HDX. Deuterium uptake was
measured by MS analysis following online pepsin digestion. Percent deute-
rium uptake for the three glucagon peptides in Peaks I0’ (black bars) and II0
(gray bars) following 48 h ofHDX (n¼ 3, mean5 SD). Intensity of Peak II0
relative to Peak I0 (white bars) (i.e., [Peak II0 intensity/Peak I0 intensity] 
100) for the three peptic fragments following 48 h of HDX (n ¼ 3,
mean5 SD).
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944 Moorthy et al.22–29 are ~36%, ~28%, and ~8%, respectively (Figs. S7
and 6).Glucagon interactions by MD simulation
MD simulations were performed to provide insight into
structural changes and early interactions involved in
glucagon fibrillation. The a-helix content of fragment 1–8
was negligible in simulations of either one or two mole-
cules, the latter allowing for effects of interaction on
secondary structure (Fig. S8, A and B). In contrast, the C-ter-
minal fragment 22–29 formed a-helices in both one- and
two-molecule simulations (Fig. S8, C and D), with greater
a-helix content in simulations of two molecules. To mimic
the experimental conditions, MD simulations were repeated
in the presence of 0.9% NaCl for a system containing two
N-terminal fragments (model 1 with model 10) and two
C-terminal fragments (model 1 with model 10). The simula-
tions were performed for 15 ns and compared to the first
15 ns of the salt-free simulations. Though a slight increaseBiophysical Journal 108(4) 937–948in secondary structure was observed in the presence of
salt, the difference in the a-helix content was minimal
(data not shown).
In light of the experimental evidence that C-terminal
interactions are involved in the early stages of fibrillation,
we aimed to identify the critical contacts for the C-C-termi-
nal interactions. When analyzing the contacts between
amino acids, the C-terminal fragment 22–29 showed at least
one contact in >94% of snapshots for all models tested. To
highlight the preferred side-chain interactions, the 10 most
frequently observed contacts averaged from three indepen-
dent simulations of two molecules of the C-terminal
fragment 22–29 were identified (Fig. 7). Hydrophobic inter-
actions between amino acids are most frequently observed
and account for eight of the 10 most frequent interactions.
In particular, Trp-25 participates in four of the 10 most
frequent interactions, i.e., with Phe-22, Val-23, Leu-26,
and Met-27. Amino acids adjacent to Trp-25 also partici-
pated in hydrophobic contacts. Phe-22, for example, is
engaged in five out of the top 10 most frequent interactions,FIGURE 7 Identification of critical contacts for
the C-terminal interactions in glucagon fibrillation
under acidic conditions. The 10 most frequent con-
tacts observed in simulations of two molecules of
glucagon fragment 22–29 are shown. Each line
represents one of the 10 interactions, which are
ordered from red to blue based on frequency. The
amino acid residues are indicated by their single
letter code with residue numbers on the left. To
see this figure in color, go online.
Glucagon Fibrillation 945four with hydrophobic or aromatic residues. An aromatic
T-shaped interaction between Phe-22 and Trp-25 is also
among the most frequent contacts.DISCUSSION
Various mechanisms have been proposed for the molecular
assembly of glucagon fibrils (23,27,28,32,58–60). One such
mechanism is based on solution-state NMR studies, in
which a glucagon trimer was shown to interact with the ex-
isting fibrils (28). HDX-NMR of mature glucagon fibrils in
the same study suggested a mechanism in which the N-ter-
minal residues are protected from deuterium exchange and
form the core of the fibrils (28), though the molecular inter-
actions at the early stage of glucagon fibrillation were not
reported. AFM studies have shown that hollow disc-shaped
oligomers are formed during the early stages of fibrillation,
perhaps consistent with the presence of glucagon trimers.
The oligomers observed by AFM were proposed to act as
precursors for the formation of protofibrils, which in turn
assemble to form mature fibrils (23,27,58,60). A study
of alanine mutants of residues Phe-6, Tyr-10, Val-23, and
Met-27 showed that the mutations alter glucagon hydropho-
bicity and impair its ability to form b-sheets, suggesting that
these residues may be important in fibril formation (32).
However, substitution of even a single residue can change
the physicochemical properties of the peptide, so that infer-
ences regarding the behavior of native glucagon based on
these mutants may not be valid.
In the studies reported here, the fibrillation of native,
monomeric glucagon was monitored using HDX-MS,
intrinsic and ThT fluorescence, turbidity, CD-spectroscopy,
and MD simulation, with the goal of identifying both the
structural changes and the residues involved in glucagon
fibrillation. HDX-MS is particularly well suited to these
goals, providing high-resolution structural information
with minimal perturbation of the native structure or the
developing oligomers and fibrils.
The fibrillation kinetics of glucagon under acidic condi-
tions were found to be sigmoidal, with a lag phase followed
by rapid fibril growth, as reported previously (24). Kinetic
analysis by turbidity and fluorescence measurements were
also consistent with previous reports and followed the pro-
file expected for nucleation-dependent fibrillation (Fig. 1).
In a nucleation-dependent process, oligomeric species are
formed during the lag phase until a sufficient number
of nuclei have been produced to initiate fibril growth. Our
HDX-MS results for fibrillating glucagon suggest the pres-
ence of two conformationally distinct populations. Unlike
the fluorescence and turbidity measurements, the kinetic
events observed with HDX-MS do not follow a sigmoidal
curve. Rather, HDX-MS data show changes in deuterium
exposure as early as 15 min from the initiation of the
fibrillation experiment, whereas the fluorescence and
turbidity measurements show significant changes only after~150 min. This suggests that HDX-MS monitors conforma-
tional changes involved in the lag phase of glucagon fibril-
lation, preceding fibrillation as detected by other methods.
With proteolytic digestion, HDX-MS can also be used to
identify the regions responsible for these early interactions,
as discussed below.
At the intact level, HDX-MS of fibrillating glucagon
suggests conformational changes between and within each
population during the transition from monomer to fibril
(Figs. 4 and S3). Results from both HDX-MS and far-UV
CD spectroscopy suggest that glucagon fibril formation is
a multistep process during which intermediates are formed
at various stages of the reaction. In solution at concentra-
tions below 1 mg/mL, glucagon has been shown to exist
as a monomer with flexible random coil structure (25,61–
63). At higher concentrations, glucagon self-associates
and undergoes a structural transition from random coil to
a-helix (61,64). CD spectral analysis of the freshly prepared
sample (0.6 mg/mL) shows that glucagon is primarily a
random coil (Fig. 2), and the single Gaussian peak distribu-
tion in the HDX-MS data (Fig. S1) confirms that glucagon is
mostly monomeric at t ¼ 0. An increase in a-helix content
by CD was observed during the lag phase, reaching a
maximum during the late-lag phase (~150 min) (Fig. 2).
This observation is consistent with a decrease in deuterium
uptake with increasing fibrillation time (Fig. 4), and sug-
gests that the a-helix formation during the early phase is
mediated by intermolecular interactions. CD spectra at later
times (220–1440 min) and ThT fluorescence measurements
suggest that fibril growth during the exponential phase
is accompanied by a structural transition from a-helix to
b-sheet.
Following pepsin digestion, HDX-MS data at the peptide
level suggest that the C-terminal region is involved in the in-
teractions and structural changes during the early stages of
glucagon fibrillation (Fig. 5). Identification of the regions
involved is based on quantitative measurement of deuterium
incorporation and protection from exchange. Quantitative
determination of sequence-dependent protection from
HDX shows that the N-terminal segment (residues 1–9)
does not participate in the interactions involved in the early
stages of fibrillation, because deuterium incorporation is
relatively unchanged for this segment. In contrast, residues
(22–29) spanning the C-terminal segment show decreases
in deuterium incorporation consistent with intermolecular
association (Fig. 5). Deuterium uptake for fragments
22–29 and 10–21 decreases from 46% to 15% and 49% to
26%, respectively, during the lag phase (0–120 min),
whereas fragments 1–6 and 1–9 did not show significant
changes during this period (Figs. 5 A and S4). These results
support the idea that the intermolecular interactions
involving the C-terminus occur during the lag phase.
HDX-MS of mature glucagon fibrils allowed the confor-
mations of glucagon within the fibrils to be captured (Figs. 6
and S7). The high deuterium uptake (~60% for 1–9, ~80%Biophysical Journal 108(4) 937–948
FIGURE 8 Proposed model for the aggregation of glucagon at acidic pH.
In solution, glucagon exists as unstructured monomers. Early stage interac-
tions in glucagon fibrillation are mediated through the C-terminal region,
which results in the formation of a-helix-rich oligomers. Oligomers formed
during the lag phase undergo structural rearrangements and elongation to
form b-sheet-rich amyloid fibrils by mechanisms not defined by the results
reported here.
946 Moorthy et al.for 10–21, and 77% for 22–29) for Peak II0 and low deute-
rium uptake (~2% for 1–9, ~6% for 10–21, and ~1% for
22–29) for Peak I0 population suggest that the former corre-
sponds to residues on the fibril surface, whereas the later
corresponds to those in the core of fibril. The intensity of
Peak II0 relative to Peak I0 for 22–29 (~8%) is less than
for other regions (~36% for 1–9 and ~28% for 10–21)
(Fig. 6), again consistent with involvement of the C-termi-
nus in fibril formation.
MD simulation of glucagon-derived peptides allowed the
interactions and structural changes to be mapped at the res-
idue level. MD simulation of two molecules of fragment 22–
29 showed a greater increase in a-helix content than was
observed in simulations of a single 22–29 fragment, sug-
gesting that intermolecular interactions induce the mutual
folding of C-terminal fragments. Simulations also showed
that the side chains from residues Phe-22, Trp-25, Val-23,
and Met-27 are predominantly involved in these interactions
(Fig. 7), in agreement with previous claims that hydropho-
bic intermolecular interactions stabilize the a-helical
conformation of glucagon (65). The high contact frequency
observed in simulations of two molecules of fragment 22–29
indicates that C-terminal fragments tend to be engaged in
intermolecular interactions, providing additional support
for the involvement of the C-terminus in the early stages
of fibrillation.
The results presented here are not in agreement with pre-
vious HDX-NMR studies at pH 2.0, in which the HDX
reaction was carried out for mature glucagon fibrils that
were then solubilized and analyzed by NMR spectroscopy
(28). In that study, amide hydrogen atoms in the N-terminal
region were found to be 20% solvent protected, whereas
other regions showed 10% protection, suggesting the
involvement of the N-terminal region in fibrillation. How-
ever, this inference is based on characterization of the end
product (mature fibril) of fibrillation and not earlier mono-
meric and oligomeric species. Here, we have used HDX-
MS to probe molecular interactions continuously from the
early stages of fibrillation and provide evidence for the
initial involvement of the C-terminus.
Overall, our results support a model for glucagon fibril-
lation in which interactions of hydrophobic residues in
the C-terminal region, especially residues Phe-22, Trp-25,
Val-23, and Met-27, initiate glucagon oligomerization at
acidic pH. The C-terminal interactions lead to the formation
of a-helix-rich oligomeric intermediates during the lag
phase. The accumulation of oligomers is followed by struc-
tural rearrangements and elongation to form b-sheet-rich
mature fibrils in the growth phase (Fig. 8). A similar mech-
anism has been proposed for insulin fibrillation, in which
a-helical oligomers are thought to be the structural nucleus
that elongates to form b-sheet-rich fibrils (66). However, the
mechanisms by which a-helix-rich glucagon oligomers un-
dergo a transition to b-sheet-rich amyloid fibrils were not
elucidated by this study, and glugacon trimers were neitherBiophysical Journal 108(4) 937–948detected experimentally nor predicted by MD simulation.
The progression from early oligomers to mature fibrils
thus is not defined by the results reported here (Fig. 8).
Finally, the results support the use of amide HDX-MS to
probe early structural changes in protein/peptide fibrillation.
Due to its rapid analysis time, HDX-MS can provide high
resolution information on conformational changes during
fibrillation that are not easily monitored by methods such
as NMR and x-ray crystallography. The results from
HDX-MS and MD simulations further suggest that residues
22–29 may be a suitable target for inhibitors designed to
inhibit glucagon fibrillation.CONCLUSIONS
HDX-MS, far-UV CD, fluorescence spectroscopy, and MD
simulation were used to map the structural transitions of
glucagon during fibrillation. At acidic pH, the early stage
interactions are mediated through the C-terminal region,
which results in the formation of species with stable a-heli-
cal structure. These species precede the formation of fibrils
as observed by fluorescence spectroscopy.SUPPORTING MATERIAL
Eight figures are available at http://www.biophysj.org/biophysj/supplemental/
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